Says approach to 2023 "prudent." Expects to achieve market growth in 2023. Says "well-positioned for 2023 and beyond." Comments taken from Q4 earnings conference call.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JNJ:
- Johnson & Johnson Reports Earnings: Did it Beat Estimate Forecasts?
- JNJ Gains after Better-than-Expected Q4 Results
- Genmab announces 2022 net sales of DARZALEX $7.98B
- Johnson & Johnson sees FY23 adjusted EPS $10.45- $10.65, consensus $10.33
- Johnson & Johnson sees FY23 adjusted operational EPS $10.40-$10.60
